Study of a new medicine to prevent flu
Part of Infections, Lungs & breathing clinical trials.
This study tests a new type of flu prevention medicine (called a monoclonal antibody) given as an injection. It is for people at higher risk of getting the flu, including those with certain health conditions or weakened immune systems.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 18 years old (implied by weight requirement, but not explicit; we assume adult) and weigh at least 40 kg (about 88 pounds).
- You must not already have the flu or COVID-19 at the time of the first dose (a rapid test will be done).
- You may have certain stable health issues like asthma, heart disease, diabetes needing insulin, chronic lung disease, moderate kidney impairment, or be 65 or older (Group A).
- Or you may have a weakened immune system because of cancer treatment, an organ or stem cell transplant, certain medications, or other immune conditions (Group B).
- You cannot have severe kidney disease, be on dialysis, or have a bleeding disorder that makes injections dangerous.
- You must not have had any flu treatment or prevention drug in the past 30 days, and you cannot be allergic to zanamivir or similar medicines.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1 study tests an investigational influenza (flu) approach in a carefully selected group of healthy adults. It may help researchers understand how the flu challenge works and how well the treatment performs and is tolerated.
This study tests an experimental medicine called TRX-100 to see if it can safely treat the flu. Healthy volunteers will be given the flu virus in a controlled setting, then the medicine, to see how well it works.
This trial tests new mRNA-based flu vaccines that may provide broader protection against different flu strains. Participants will receive the vaccine and be monitored for safety and their immune response.
This study tests a new drug, RLX-2508-102, in healthy people to see how safe it is and how the body handles it. It's an early step to learn if the medicine could be used for future treatments.
This study tests an experimental flu vaccine (BPL-1357) in healthy volunteers who will later be exposed to H1N1 flu virus in a controlled setting, to see if the vaccine can prevent or reduce illness.
This study tests a new flu vaccine to see how well it helps the body fight off the flu. It is for generally healthy adults aged 18 to 59 who have not had the flu recently.
Hear when a new Influenza trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.